SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Trametinib-^{13}C-d$_3$

Item No. 29144

Formal Name:	N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6-methyl-8-(methyl-^{13}C-d$_3$)-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl] phenyl]-acetamide
MF:	$C_{25}[^{13}C]H_{20}D_3FIN_5O_4$
FW:	619.4
Chemical Purity:	≥98% (Trametinib)
Deuterium Incorporation:	≥99% deuterated forms (d$_1$-d$_3$); ≤1% d$_0$
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Trametinib-^{13}C-d$_3$ is intended for use as an internal standard for the quantification of trametinib (Item No. 16292) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Trametinib-^{13}C-d$_3$ is supplied as a solid. A stock solution may be made by dissolving the trametinib-^{13}C-d$_3$ in the solvent of choice, which should be purged with an inert gas. Trametinib-^{13}C-d$_3$ is soluble in DMSO.

Description

Trametinib is an inhibitor of MEK1 and -2.[1] It inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC$_{50}$s = 3.4 and 1.8 nM, respectively) and MEK2 (IC$_{50}$s = 1.6 and 0.92 nM, respectively). Trametinib inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC$_{50}$s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC$_{50}$s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC$_{50}$ = >10,000 nM). It reduces tumor growth in HT-29 and COLO 205 mouse xenograft models when used at doses of 0.3 and 1 mg/kg per day. Trametinib (0.03 and 0.1 mg/kg per day) also decreases *M. tuberculosis*-induced increases in hind paw volume in a rat model of arthritis.[2] Formulations containing trametinib, in combination with dabrafenib, have been used in the treatment of B-RAF^{V600E} mutant metastatic melanoma.

References

1. Yamaguchi, T., Kakefuda, R., Tajima, N., *et al.* Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines *in vitro* and *in vivo*. *Int. J. Oncol.* **39(1),** 23-31 (2011).
2. Yamaguchi, T., Kakefuda, R., Tanimoto, A., *et al.* Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: A comparison with leflunomide. *Inflamm. Res.* **61(5),** 445-454 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM